As of Sep 26
| -0.72 / -3.84%|
The 6 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 19.50, with a high estimate of 25.00 and a low estimate of 18.00. The median estimate represents a +8.15% increase from the last price of 18.03.
The current consensus among 7 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.